Brijjit® for Wound Closure in Gender Affirming Mastectomies

Not Applicable

Withdrawn

• Conditions: Mastectomy
• Interventions: Device: Brijjit®

• Registration Number: NCT05368519
• Lead Sponsor: NYU Langone Health

Brief Summary

This study will evaluate the use of Brijjit® for wound closure in individuals undergoing bilateral double incision gender affirming mastectomies with a single surgeon (Rachel Bluebond-Langner, MD). The study will be a randomized prospective interventional study utilizing internal controls (one side of chest receives intervention, other serves as control). Primary endpoints will include scar appearance/quality and wound complications

Detailed Description

The hypothesis of this study is that the use of Brijjit® FMTB will result in improved scar outcomes as measured by both patient and treating physician as compared to traditional suture based wound closure methods. As mentioned, at present there is no standard of care for wound closure following double incision GAM, therefore an internal control approach will be taken with patients serving as their own controls. This will be achieved by having one side of the chest receive the of Brijjit® FMTB (intervention) in addition to suture closure of the skin, while the other side will be closed with traditional methods, a combination of sutures and steri-stripsTM (control).

Study Timeline

• Study First Submitted: 2022-05-03
• Study First Submitted QC: 2022-05-09
• Study First Posted: 2022-05-10
• Study Start: 2022-06-01
• Status Verified: 2022-08
• Last Update Submitted: 2022-08-05
• Last Update Posted: 2022-08-09
• Primary Completion: 2024-04-19
• Study Completion: 2024-04-19

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Patient self-identifies as Transgender or Gender Expansive
• Patient will undergo primary bilateral double incision mastectomy at NYULH
• All clinical criteria to be eligible for primary mastectomy must be met
• Ability to care for donor site and adhere to wound therapy (either solo or with care-giver assistance)
• Willingness to return for scheduled follow-up visits through 1 year post-operatively
• 18 years of age or older
• English Speaking

Exclusion Criteria

• Individuals with previously diagnosed allergies or a history of adverse effects related to adhesives / adhesive tapes
• Individuals with a history of the following prescription medication use in the last year: Accutane, Systemic glucocorticoids and/or Local glucocorticoids or immunosuppressants (i.e. topical tacrolimus, topical clindamycin etc.) at the intervention site
• Individuals with a history of significant scarring or adverse scarring (hypertrophic scars or keloid scars)
• Individuals with pre-existing scars at the GAM wound closure site
• Individuals with a disorder known to negatively affect wound healing (i.e. autoimmune disease, connective tissue disease)
• Individuals with malnutrition
• Individuals with a BMI >30 kg/m2
• Individuals with a history of radiation therapy
• Active smokers or smokeless nicotine use
• History of Previous Mastectomy
• Patient is actively immunosuppressed i.e. AIDS (HIV+ acceptable), or Systemic immunosuppressants
• Patients unable to attend post-operative follow-ups in person
• Patients with a considerable history of medical non-compliance
• Patient will receive GAM not including double incisions (i.e. periareolar)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Right chest with Brijjit® FMTB	Brijjit®	Patients will be assigned to have their right chest closure completed via Brijjit® FMTB. While the other chest (not selected for intervention) will be closed via traditional suture-based methods and will serve as an internal control.
Left chest with Brijjit® FMTB	Brijjit®	Patients will be assigned to have their left chest closure completed via Brijjit® FMTB. While the other chest (not selected for intervention) will be closed via traditional suture-based methods and will serve as an internal control.

Primary Outcome Measures

Name	Time	Method
Subjective scar evaluation by patient outcomes using POSAS	12-months post-surgery visit	Patient and Observer assessment scale (POSAS) will be used to visually assess their scar appearance and complete the 10-point scale. The patient scale will include questions regarding pain, itch, thickness, color, stiffness, irregularity, and overall opinion. Each item on both scales has a score of 1 to 10. The lowest score is 1 and corresponds to the normal skin situation. The total score of both scales can be calculated simply by adding the scores of each of the six items. The total score will range from 6 to 60.
Subjective scar evaluation by surgeon outcomes using POSAS	12-months post-surgery visit	Clinician will visually assess the scar appearance during the visit and complete the 10-point scale. The observer scale will include items with subcategories related to vascularity, pigmentation, relief/texture, thickness, pliability, surface area and overall opinion.Scores are tabulated out of 70. Each item on both scales has a score of 1 to 10. The lowest score is 1 and corresponds to the normal skin situation. The total score of both scales can be calculated simply by adding the scores of each of the six items. The total score will range from 6 to 60.
Photographic assessment for objective scar evaluation	12-months post-surgery visit	Standard and close-up photography (part of standard of care) will be utilized for evaluation of the appearance surgical scars. These photographs will be taken utilizing the Nikon D7200 at screening/baseline, week 2, week 4, week 6, week 8, 3-month post-surgery, 6-months post-surgery and 12-months post-surgery. There will be no statistical analyses employed on the photographs
Colorimetry of Scar	12-months post-surgery visit	The Pantone SkinTone Guide is a handheld tool consisting of 110 color swatches that realistically mimic human skin tones, with stepwise variations in lightness and undertone. The guide was specifically formulated to be the closest physical representation of skin colors and is the only internationally available color standard to accurately match skin tones. Each SkinTone number is comprised of a four-digit alphanumeric number; the first two numbers reflect the hue or undertone of the skin while the second two represent the tone or lightness and darkness of the skin. This tool will be utilized to establish a clinically acceptable objective assessment for assessing the coloring of patients' scars.

Trial Locations

Locations (1)

NYU Langone Health; 🇺🇸 New York, New York, United States